Top Story
Research scientists brace for layoffs as stimulus cash dries up
The stimulus bill that pumped more than $8 billion into biomedical research projects in the U.S. is set to end at the end of the month. And the surge of research work that it helped spawn is likely to come to a quick stop, triggering stinging job losses as research scientists jockey for a piece of a much smaller pie. ArticleLatest News
Muscle strength emerging as a major R&D focus
Sarcopenia may one day become the new osteoporosis for drug makers. The regulatory pathway may be hazy, but drug developers like GlaxoSmithKline are zeroing in on sarcopenia--the loss of muscle mass and strength--as a likely source of future blockbusters. StoryFrom The Network
Also Noted
Cancer Research
A researcher at the University of Arizona is laying the groundwork for a clinical trial to test the effectiveness of a new therapy that promises to stop tumor growth. Joyce Schroeder believes that she is on to a new approach to treat a subgroup of breast cancer patients with so-called "triple negative" cancer. Schroeder believes that two proteins--MUC1 and EGFR--spur the cancer together and her new drug causes EGFR to degrade in the cancer cell, triggering its death. The Susan G. Komen for the Cure foundation has helped finance some of the research work. Report
Stem Cell Research
Read more >>Press Releases
- PPD Appoints Neil McCullough, Ph.D., Vice President of Quality Management Systems
- StemCells, Inc.'s Technology Used to Create First Genetically Engineered Rat Derived From Rat Embryonic Stem Cells
- METHYLGENE APPOINTS DR. MARTIN GODBOUT AS CHAIRMAN OF THE BOARD OF DIRECTORS
- Easton Pharmaceuticals Inc. Announces Experienced CFO Appointment to Management Team
- LifeSciences British Columbia Appoints Don Enns as President
- STATegics, Inc. Announces Patent Issued by the U.S. Patent and Trademark Office for Small Molecule Thrombopoietin Mimetics
